Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATLAS: UGN-102 in LG-IR-NMIBC
NCT04688931Phase 3Terminated
- Sponsor
- UroGen Pharma
- Start
- Feb 2021
- Primary completion
- Mar 2023
- Modality
- DNA Intercalators/Alkylators, Hydrogel Systems
- Countries
- 10
01
Overview
A Phase 3 trial of zusduri in non-muscle-invasive bladder cancer (NMIBC), sponsored by UroGen Pharma. Started Feb 2021; status: terminated.
02
Drugs
zusduri
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on NCT04688931.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04688931.